AnaptysBio, Inc. (ANAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$45.58-4.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ANAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -49.6% |
| Our one-year growth estimate | diamond | 2.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 51.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
ANAB — earnings miss
Dated 2026-05-12
Results of Operations and Financial Condition. On May 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Why it matters: An approval would clear a key step for Vanda’s GPP drug and support Anaptys’ royalty stream.
Supportive ifFDA approves Quimilza for GPP by its Dec. 12, 2026 target date.
Worry ifFDA issues a complete response letter, rejects the application, or misses the Dec. 12 target date.
Why it matters: Anaptys says its new model has few staff and low costs. Cash fell by $47.5 million in the six months to June 30.
Supportive ifA later earnings report shows operating cash use under $72.9 million. This covers six months after the spin-off.
Worry ifA later report shows operating cash use of $72.9 million or more over six months after the spin-off.
Why it matters: Approval could add a new use for Jemperli. Anaptys earns royalties tied to the drug.
Supportive ifFDA approves Jemperli for untreated stage II/III dMMR/MSI-H rectal cancer by the Feb. 2027 action date, or sooner.
Worry ifFDA does not approve the use by the Feb. 2027 action date, or asks for more data.
Why it matters: The plan is a stated way to return value to shareholders, but no shares had been bought by June 30.
Supportive ifA company filing or earnings release reports share purchases under the $100 million plan before it expires Dec. 31, 2026.
Worry ifThe plan expires on Dec. 31, 2026, with no shares repurchased, or Anaptys ends it sooner.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$175 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $548 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,492 loss on $10,000 · 34.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Jemperli royalties are Anaptys’ main income stream. Faster sales growth supports its stated $390 million annual royalty goal.
Watch forGSK reports Jemperli sales growth at or above 26% year over year, matching or beating Q2 2026 growth.
Also watch forGSK reports Jemperli sales growth below 26% year over year in a later quarter.
Why it matters: Anaptys is seeking the return of Jemperli rights. The ruling could affect its royalty deal and future cash.
Watch forThe court grants Anaptys reversion of Jemperli rights, or grants key relief sought by Anaptys.
Also watch forThe court denies Anaptys’ request to regain Jemperli rights, or rules for GSK and Tesaro.